| Primary |
| Chemotherapy |
10.9% |
| Drug Use For Unknown Indication |
10.9% |
| Neoplasm Malignant |
10.9% |
| Product Used For Unknown Indication |
10.9% |
| Non-hodgkin's Lymphoma Unspecified Histology Aggressive Refractory |
8.7% |
| Sedation |
6.5% |
| Endotracheal Intubation |
4.3% |
| Secondary Prevention |
4.3% |
| Sepsis |
4.3% |
| Vasculitis |
4.3% |
| Wegener's Granulomatosis |
4.3% |
| Aphthous Stomatitis |
2.2% |
| Blood Potassium Decreased |
2.2% |
| Cancer Pain |
2.2% |
| Coagulopathy |
2.2% |
| Epilepsy |
2.2% |
| Hyperglycaemia |
2.2% |
| Hypothyroidism |
2.2% |
| Hypovitaminosis |
2.2% |
| Nausea |
2.2% |
|
| Vomiting |
42.9% |
| Off Label Use |
14.3% |
| Skin Burning Sensation |
14.3% |
| Stevens-johnson Syndrome |
14.3% |
| Swelling Face |
14.3% |
|
| Secondary |
| Product Used For Unknown Indication |
27.3% |
| Drug Use For Unknown Indication |
15.1% |
| Prophylaxis |
11.9% |
| Lymphoma |
5.6% |
| B-cell Lymphoma |
4.8% |
| Rhabdomyosarcoma |
4.5% |
| Wegener's Granulomatosis |
3.4% |
| Neoplasm Malignant |
3.4% |
| Systemic Lupus Erythematosus |
2.9% |
| Infection |
2.6% |
| Non-hodgkin's Lymphoma |
2.4% |
| Premedication |
2.2% |
| Chemotherapy |
2.1% |
| Hodgkin's Disease |
2.0% |
| Nausea |
1.9% |
| Acute Lymphocytic Leukaemia |
1.7% |
| Bone Sarcoma |
1.6% |
| Nasopharyngeal Cancer Recurrent |
1.5% |
| Sarcoma |
1.5% |
| Central Nervous System Lymphoma |
1.4% |
|
| Vomiting |
14.9% |
| Febrile Neutropenia |
10.6% |
| Disease Progression |
9.9% |
| Encephalopathy |
6.4% |
| Pyrexia |
6.4% |
| Weight Decreased |
5.7% |
| Hypertriglyceridaemia |
5.0% |
| Jaundice |
5.0% |
| Agranulocytosis |
4.3% |
| Neutropenia |
4.3% |
| Ovarian Failure |
4.3% |
| Cytolytic Hepatitis |
3.5% |
| Neuropathy Peripheral |
3.5% |
| Somnolence |
2.8% |
| White Blood Cell Count Decreased |
2.8% |
| Anaemia |
2.1% |
| Pancreatitis Acute |
2.1% |
| Paranoia |
2.1% |
| Renal Failure |
2.1% |
| Respiratory Distress |
2.1% |
|
| Concomitant |
| Product Used For Unknown Indication |
18.8% |
| Drug Use For Unknown Indication |
11.1% |
| Breast Cancer |
10.8% |
| Prophylaxis |
9.2% |
| Infection Prophylaxis |
6.1% |
| Diffuse Large B-cell Lymphoma |
5.6% |
| Idiopathic Thrombocytopenic Purpura |
5.0% |
| Hodgkin's Disease |
3.9% |
| Immune Thrombocytopenic Purpura |
3.8% |
| Stem Cell Transplant |
3.4% |
| Prophylaxis Against Graft Versus Host Disease |
2.8% |
| Acute Lymphocytic Leukaemia |
2.7% |
| Infection |
2.6% |
| B-cell Lymphoma |
2.4% |
| Non-hodgkin's Lymphoma |
2.1% |
| Prophylaxis Of Nausea And Vomiting |
2.1% |
| Bone Marrow Conditioning Regimen |
2.0% |
| Premedication |
2.0% |
| Chemotherapy |
1.8% |
| Lymphoma |
1.8% |
|
| White Blood Cell Count Decreased |
10.5% |
| Tremor |
8.8% |
| Vomiting |
8.8% |
| Pyrexia |
7.0% |
| Sepsis |
6.4% |
| Febrile Neutropenia |
5.8% |
| Renal Impairment |
5.8% |
| Neutropenia |
5.3% |
| Pulmonary Embolism |
5.3% |
| Neuroblastoma |
4.7% |
| Pancytopenia |
4.7% |
| Thrombocytopenia |
4.1% |
| Hyponatraemia |
3.5% |
| Septic Shock |
3.5% |
| Leukopenia |
2.9% |
| Transaminases Increased |
2.9% |
| Visual Acuity Reduced |
2.9% |
| Cytolytic Hepatitis |
2.3% |
| Drug Interaction |
2.3% |
| General Physical Health Deterioration |
2.3% |
|
